Science Corporation has reached a major milestone in vision-restoration technology by implanting its PRIMA chip in its first patient with Stargardt disease, a genetic condition that can cause progressive central vision loss.
The company, led by Neuralink co-founder and former president Max Hodak, is positioning PRIMA as part of a broader roadmap toward novel brain-computer interface technology. While still early, the implant represents a tangible step from lab development toward helping patients in clinical settings.
Why this matters
Stargardt disease can significantly affect reading, facial recognition, and daily independence. A successful vision-restoring implant could open new possibilities for people living with retinal degeneration, especially where conventional treatments remain limited.
- Real patient deployment: The technology has moved beyond concept into implantation.
- Accessibility potential: Restoring useful vision could improve independence and quality of life.
- Future BCI progress: The work may inform broader brain-computer interface development.
Although more clinical evidence will be needed, this first Stargardt patient implant is an encouraging sign that advanced neurotechnology is steadily moving closer to practical medical impact.